Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis.

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Pulmonary Circulation Pub Date : 2024-10-11 eCollection Date: 2024-10-01 DOI:10.1002/pul2.12441

Oksana A Shlobin, Gary Bruce, Gabriela Gomez-Rendon, Martha Kingman, Mohammad Rahman, Frances Rogers, Sean Studer, Tobore Tobore, Colleen McEvoy

引用次数: 0

Abstract

This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.

查看原文本刊更多论文

影响马西替坦和西乐昔帕患者坚持率的做法利用肺动脉高压临床站点和患者标准（PERSIST）：一项美国定性分析。

这项真实世界研究从 23 名医疗保健专业人员（HCPs）和 134 名肺动脉高压患者的角度，探讨了 2019 年至 2022 年期间影响坚持使用马西替坦和 selexipag 治疗的因素。患者/医护人员的持续沟通和教育是坚持治疗的关键因素，早期讨论和处理副作用也是如此。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonary Circulation Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.20

自引率

11.50%

发文量

153

审稿时长

15 weeks

期刊介绍： Pulmonary Circulation''s main goal is to encourage basic, translational, and clinical research by investigators, physician-scientists, and clinicans, in the hope of increasing survival rates for pulmonary hypertension and other pulmonary vascular diseases worldwide, and developing new therapeutic approaches for the diseases. Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a wide readership of specialists in order to improve patient care and treatment outcomes.